Results 21 to 30 of about 76,746 (287)

Histone deacetylase inhibitors promote breast cancer metastasis by elevating NEDD9 expression

Signal Transduction and Targeted Therapy, 2023
Histone deacetylase (HDAC) is a kind of protease that modifies histone to regulate gene expression, and is usually abnormally activated in tumors. The approved pan-HDAC inhibitors have demonstrated clinical benefits for patients in some hematologic ...
Zonglong Hu, Fan Wei, Yi Su, Yafang Wang, Yanyan Shen, Yanfen Fang, Jian Ding, Yi Chen   +7 more
doaj   +1 more source

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells

Frontiers in Oncology, 2021
We have extended our analyses of HDAC inhibitor biology in sarcoma. The multi-kinase inhibitor axitinib interacted with multiple HDAC inhibitors to kill sarcoma cells.
Jane L. Roberts, Laurence Booth, Andrew Poklepovic, Paul Dent   +3 more
doaj   +1 more source

Combinations of isoform-targeted histone deacetylase inhibitors and bryostatin analogues display remarkable potency to activate latent HIV without global T-cell activation [PDF]

, 2017
Current antiretroviral therapy (ART) for HIV/AIDS slows disease progression by reducing viral loads and increasing CD4 counts. Yet ART is not curative due to the persistence of CD4+ T-cell proviral reservoirs that chronically resupply active virus ...
Albert, Brice J, Barnes, Alexander B, Kyei, George B, Marshall, Garland R, Niu, Austin, Ramani, Rashmi, Ratner, Lee, Wender, Paul A, Williams, Robert M   +8 more
core   +2 more sources

Checkpoint Blockade Rescues the Repressive Effect of Histone Deacetylases Inhibitors on γδ T Cell Function

Frontiers in Immunology, 2018
Histone deacetylases (HDAC) are one of the key epigenetic modifiers that control chromatin accessibility and gene expression. Their role in tumorigenesis is well established and HDAC inhibitors have emerged as an effective treatment modality.
Sajad A. Bhat, Sajad A. Bhat, Disha Mohan Vedpathak, Disha Mohan Vedpathak, Shubhada V. Chiplunkar, Shubhada V. Chiplunkar   +5 more
doaj   +1 more source

Inhibition of histone deacetylases attenuates tumor progression and improves immunotherapy in breast cancer

Frontiers in Immunology, 2023
Breast cancer is one of the common malignancies with poor prognosis worldwide. The treatment of breast cancer patients includes surgery, radiation, hormone therapy, chemotherapy, targeted drug therapy and immunotherapy. In recent years, immunotherapy has
Bi Lian, Xiaosong Chen, Kunwei Shen
doaj   +1 more source

HDAC-mediated control of ERK- and PI3K-dependent TGF-β-induced extracellular matrix-regulating genes [PDF]

, 2010
Histone deacetylases (HDACs) regulate the acetylation of histones in the control of gene expression. Many non-histone proteins are also targeted for acetylation, including TGF-ß signalling pathway components such as Smad2, Smad3 and Smad7. Our studies in
Andrew D. Rowan, Bain, Cao, Chen, Chen, Cho, Clayton, David A. Young, de Ruijter, Denker, Dennler, Derynck, Dylan R. Edwards, Fecteau, Gary J. Litherland, Ghosh, Glenisson, Glozak, Gottlicher, Gregoretti, Gurvich, Hazzalin, Horowitz, Ian M. Clark, Khan, Kobayashi, Kouzarides, Kuang, Kwak, Le Pabic, Le Pabic, Lee, Leon Pybus, Li, Lien, Litherland, Mahlknecht, Matt J. Barter, Michaelis, Rombouts, Shi, Tim E. Cawston, Togi, Tu, Vannini, Verdin, Wang, Whitmarsh, Wrana, Xu, Yamaguchi, Yoshikawa, Young, Yu, Zhang   +54 more
core   +1 more source

Histone deacetylase 2-mediated deacetylation of the Ribonuclease 1 promoter in inflamed human endothelial cells [PDF]

, 2020
Endothelial cells (ECs) function as protective barrier to separate the blood from the surrounding tissue by conducting crucial roles in regulation and maintenance of vascular homeostasis, such as control of vessel permeability or coagulation.
Bedenbender, Katrin
core   +1 more source

A possible link to uracil DNA glycosylase in the synergistic action of HDAC inhibitors and thymidylate synthase inhibitors

Journal of Translational Medicine, 2020
It is well established that thymidylate synthase inhibitors can cause cellular toxicity through uracil DNA glycosylase (UNG2)-dependent pathways. Additionally, thymidylate synthase inhibitors and HDAC inhibitors are known to act synergistically in a ...
Meredith S. Showler, Brian P. Weiser
doaj   +1 more source

Histone deacetylase adaptation in single ventricle heart disease and a young animal model of right ventricular hypertrophy. [PDF]

, 2017
BackgroundHistone deacetylase (HDAC) inhibitors are promising therapeutics for various forms of cardiac diseases. The purpose of this study was to assess cardiac HDAC catalytic activity and expression in children with single ventricle (SV) heart disease ...
A Cevik, A Correa-Villasenor, A deAlmeida, A Granger, A Kulkarni, AP Vlahos, C Scholz, Carlin S Long, CL Antos, D Sedmera, DD Lemon, DJ Cao, Douglas D Lemon, J Lu, JP Cardinale, JW Newburger, JW Rossano, JW Rossano, Karin Nunley, Katharina M Lutter, KB Schuetze, Kimberly M Demos-Davies, KM Demos-Davies, M Tanno, MA Cavasin, MA Cavasin, Maria A Cavasin, MP Gupta, OA O'Connor, PA Marks, PC Frommelt, Q Yang, R Kirk, RG Ohye, S Chen, Sam Payne, SD Miyamoto, SD Miyamoto, SD Miyamoto, Shelley D Miyamoto, SJ Nakano, SK Mani, SM Williams, TA McKinsey, TG Gillette, Timothy A McKinsey, VM Klimek, Weston W Blakeslee, WJ Kowalski, WW Blakeslee   +49 more
core   +1 more source

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors

Pharmaceuticals, 2014
Histone deacetylases (HDACs) enzymes, which affect the acetylation status of histones and other important cellular proteins, have been recognized as potentially useful therapeutic targets for a broad range of human disorders.
Elizabeth A. Thomas
doaj   +1 more source